Repligen/$RGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Ticker
$RGEN
Sector
Primary listing
Employees
1,778
Headquarters
Website
Repligen Metrics
BasicAdvanced
$8.3B
5,774.19
$0.03
1.13
-
Price and volume
Market cap
$8.3B
Beta
1.13
52-week high
$182.52
52-week low
$102.97
Average daily volume
1.1M
Financial strength
Total debt to equity
33.276
Interest coverage (TTM)
2.13%
Profitability
EBITDA (TTM)
127.779
Gross margin (TTM)
51.90%
Net profit margin (TTM)
0.25%
Operating margin (TTM)
6.95%
Effective tax rate (TTM)
62.72%
Revenue per employee (TTM)
$400,000
Management effectiveness
Valuation
Price to earnings (TTM)
5,774.188
Price to revenue (TTM)
11.659
Price to book
4.01
Price to tangible book (TTM)
15.26
Growth
Revenue change (TTM)
11.74%
Earnings per share change (TTM)
-117.56%
3-year revenue growth (CAGR)
-4.05%
10-year revenue growth (CAGR)
24.60%
3-year earnings per share growth (CAGR)
-79.35%
10-year earnings per share growth (CAGR)
-20.77%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Bulls say / Bears say
Revenue in Q2 2025 reached $182 million, up 15% year-over-year with 17% organic non-COVID growth and orders rising over 20%, underscoring strong, broad-based demand across all franchises (GlobeNewswire)
The company raised its full-year 2025 revenue guidance to $715 million–$735 million, reflecting 12.5%–15.5% organic non-COVID growth, signaling management’s confidence in underlying business momentum (GlobeNewswire)
Repligen completed the $70 million acquisition of 908 Devices’ desktop PAT portfolio on March 4, 2025, enhancing its process analytical technology offering and providing a foundation for expanded digitalization solutions across upstream and downstream workflows (Nasdaq)
GAAP gross margin narrowed to 50.0% in Q2 2025 from 51.3% a year ago, highlighting rising cost pressures and margin compression in key franchises (GlobeNewswire)
Management has disclosed material weaknesses in internal control over financial reporting as of March 31, 2025, creating a heightened risk of future restatements or financial misstatements (SEC 10-Q)
Ongoing supply chain and raw material cost inflation remains elevated, requiring price increases and productivity improvements to offset, which may not fully mitigate margin erosion if inflation persists (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repligen stock?
Repligen (RGEN) has a market cap of $8.3B as of November 06, 2025.
What is the P/E ratio for Repligen stock?
The price to earnings (P/E) ratio for Repligen (RGEN) stock is 5774.19 as of November 06, 2025.
Does Repligen stock pay dividends?
No, Repligen (RGEN) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Repligen dividend payment date?
Repligen (RGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Repligen?
Repligen (RGEN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.